News
UPDATE ON BEMCENTINIB’S INVOLVEMENT IN POTENTIAL TREATMENT OF COVID-19 PANDEMIC
July 28, 2020
BerGenBio in late stage set-up phase to sponsor and conduct a clinical study using bemcentinib…
Read MoreBERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I/II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINIB
July 20, 2020
Bergen, Norway, 20 July 2020 –BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read More
BERGENBIO ANNOUNCES POSITIVE interim CLINICAL AND TRANSlaTIONAL DATA from Phase II trial of BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN checkpoint inhibitor refractory NSCLC PATIENTS
June 25, 2020
6 of 7 checkpoint inhibitor refractory cAXL-positive patients report clinical benefit 12 evaluable patients for cAXL…
Read MoreBERGENBIO ANNOUNCES CHANGE TO PRESENTATION TIME AT Next Gen Immuno-Oncology Congress
June 24, 2020
Bergen, Norway, 24 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBerGenBio to Present at the Upcoming Virtual European Biotech Investor Day 2020
June 23, 2020
Bergen, Norway, June 23, 2020 – BerGenBio, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors…
Read MoreBERGENBIO TO PRESENT TOP LINE TRANSLATIONAL PHASE II DATA WITH BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN NSCLC PATIENTS AT Next Gen Immuno-Oncology Congress
June 15, 2020
Bergen, Norway, 15 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159